Compare Moody's Corporation (MCO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Moody's Corporation trades at $458.77 (market cap $77.87B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Moody's Corporation and Regeneron Pharmaceuticals Inc are close in size by market cap, and Moody's Corporation pays the higher dividend (0.92%). Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| MCO | REGN | |
|---|---|---|
Market Cap | $77.87B | $76.40B |
Volume | 633,412 | 626,381 |
Sector | Financials | Health |
52-Week High | $539.61 | $852.03 |
52-Week Low | $412.23 | $557.73 |
Typical Hold Time | 132 Days | 107 Days |
Enterprise Value | $83.89B | $71.12B |
Dividend Yield | 0.92% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $458.69, up 1.41% with strong fundamentals including 34.25% net income margin and 80.15% ROE. The stock shows bearish technical signals but has consistently beaten earnings estimates in recent quarters. Recent developments include a minority stake acquisition in Philippine Rating Services and continued leadership in risk analytics, with the company ranking #1 in Chartis RiskTech100 for the fifth consecutive year.
Despite technical weakness, Moody's maintains strong profitability and analyst support with 56% buy ratings and a $536.40 consensus target. Key risks include high valuation multiples and potential market volatility, but the company's dominant market position and consistent earnings growth support long-term investment appeal.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
